ライフサイエンスコーパス: upper respiratory tract

1 s pneumoniae begins with colonization of the upper respiratory tract.

2 h is associated with virus attachment to the upper respiratory tract.

3 ceded by excess bacterial density within the upper respiratory tract.

4 logous H1N1 virus challenge infection in the upper respiratory tract.

5 ve binding to human receptors present in the upper respiratory tract.

6 rrelate with the degree of protection in the upper respiratory tract.

7 e colonizes the mucosal surface of the human upper respiratory tract.

8 cantly reduced in colonization of the murine upper respiratory tract.

9 lycan similarity between the human and swine upper respiratory tract.

10 se and initiates infection by colonizing the upper respiratory tract.

11 m that initiates infection by colonizing the upper respiratory tract.

12 ycans, thereby promoting colonization of the upper respiratory tract.

13 d efficiently in lung tissues as well as the upper respiratory tract.

14 t inhibit RSV replication effectively in the upper respiratory tract.

15 lethality and replication efficiency in the upper respiratory tract.

16 strains retained the ability to colonize the upper respiratory tract.

17 t and decreasing the bacterial burden in the upper respiratory tract.

18 potently inhibited viral replication in the upper respiratory tract.

19 that colonizes the human oral cavity and the upper respiratory tract.

20 s believed to begin with colonization of the upper respiratory tract.

21 ns, with virus replication restricted to the upper respiratory tract.

22 es and initiates infection by colonizing the upper respiratory tract.

23 ans and is prone to persistently inhabit the upper respiratory tract.

24 linkage on epithelial cells of the lungs and upper respiratory tract.

25 orchestrates immune responses to Ags in the upper respiratory tract.

26 piratory tract and partial protection in the upper respiratory tract.

27 n that initiates infection by colonizing the upper respiratory tract.

28 enesis or mycoplasma organism numbers in the upper respiratory tract.

29 orrelation with the replication in the human upper respiratory tract.

30 by suppressing inflammatory processes of the upper respiratory tract.

31 preceded by an unidentified infection of the upper respiratory tract.

32 on from homologous wt virus challenge in the upper respiratory tract.

33 -negative human pathogen that resides in the upper respiratory tract.

34 the ca vaccine viruses was restricted to the upper respiratory tract.

35 ased viral replication in both the lower and upper respiratory tracts.

36 ses were reduced sixfold and 160-fold in the upper respiratory tract and 3,200-fold and 4,000-fold in

37 (NTHi) initiates infection by colonizing the upper respiratory tract and is a common cause of localiz

38 important human pathogen that colonizes the upper respiratory tract and is also the major cause of m

39 ae is an opportunistic pathogen of the human upper respiratory tract and is often found to cause infl

40 had significantly lower virus titers in the upper respiratory tract and less-severe disease.

41 Review looks at the landscape ecology of the upper respiratory tract and mouth and seeks greater clar

42 hich supported virus replication only in the upper respiratory tract and not in the lower respiratory

43 of s-LAIV led to complete protection in the upper respiratory tract and partial protection in the lu

44 s in efficient clearance of virus within the upper respiratory tract and rarely produces severe disea

45 tious diseases, especially infections of the upper respiratory tract and skin.

46 ata suggest that there is persistence in the upper respiratory tract and that this is key in the esta

47 Respiratory viruses initially infect the upper respiratory tract and then progress to lower respi

48 Pan/99 virus grew to high titers in the upper respiratory tract and was shed in nasal washings o

49 Most infections (47%) involved the upper respiratory tract and were minor.

50 umococcal species that naturally inhabit the upper respiratory tract and yielded 97% (142/146) sensit

51 ucous layer coating the nasal epithelium and upper respiratory tract, and are cleared by ciliary moti

52 ly reduced (P<.05) and was restricted to the upper respiratory tract, and spread of virus to the brai

53 infectious dose, grow to high titers in the upper respiratory tract, and transmit efficiently among

54 of an H5N1 influenza virus in the mammalian upper respiratory tract, and yet it was insufficient to

55 AV primarily infects epithelial cells of the upper respiratory tract, APCs are also susceptible.

56 The epithelial surfaces of the upper respiratory tract are continuously exposed to a wi

57 ower gastrointestinal tract, rather than the upper respiratory tract, as the likely source community

58 condary bacterial pneumonia caused by common upper respiratory-tract bacteria in most influenza fatal

59 condary bacterial pneumonia caused by common upper respiratory-tract bacteria.

60 s role in otitis media (OM), the most common upper respiratory tract bacterial infectious disease in

61 all viruses replicated to high titers in the upper respiratory tract but produced only mild illness.

62 atically colonize the mucosal surface of the upper respiratory tract, but also occasionally cause inv

63 s, all of the viruses replicated well in the upper respiratory tract, but the equine viruses replicat

64 pneumococcus may promote colonization of the upper respiratory tract by enhancing the ability of the

65 mptomatic and persistent colonization of the upper respiratory tract by Neisseria meningitidis occurs

66 sampled by bronchoalveolar lavage (BAL) and upper respiratory tract by oropharyngeal wash (OW).

67 Molecular detection of RVs from the upper respiratory tract can be prolonged, complicating e

68 Whereas upper respiratory tract carriage precedes disease for bo

69 within the lungs; however, their effects on upper respiratory tract carriage remain unknown.

70 noculation of Ply+ pneumococci both enhanced upper respiratory tract cell apoptosis and prolonged sur

71 cing pneumococci elicited significantly more upper respiratory tract cell apoptosis in wild-type mice

72 ceptibility to early allergic sensitization, upper respiratory tract colonization with bacterial path

73 association between colonization density of upper respiratory tract colonizers and pathogen-specific

74 cing the numbers of B. bronchiseptica in the upper respiratory tract compared to wild-type controls.

75 as less frequently observed in patients with upper respiratory tract disease only and more frequently

76 sion, and a higher prevalence of destructive upper respiratory tract disorders at the time of enrollm

77 s by county were estimated for uncomplicated upper respiratory tract encounters (acute otitis media,

78 Of 246866 uncomplicated upper respiratory tract encounters, antibiotics were dis

79 NiV initially replicated in the upper respiratory tract epithelium, whereas HeV initiate

80 ee DNA liberated from other organisms in the upper respiratory tract, facilitating immune evasion and

81 entifying the molecular changes that enhance upper respiratory tract fitness, increased resistance to

82 pathogen that is commonly found in the human upper respiratory tract, has only four identified two-co

83 g (hazard ratio, 1.71 [CI, 1.04 to 2.81]) or upper respiratory tract (hazard ratio, 1.73 [CI, 1.04 to

84 ines) and treat (antivirals) infection, this upper respiratory tract human pathogen remains a global

85 t commonly, visits were reportedly for acute upper respiratory tract illnesses (sore throat, 34.3%; e

86 ard-dose group, or number of parent-reported upper respiratory tract illnesses between groups (625 fo

87 Upper respiratory tract illnesses have been associated w

88 ns, noninfluenza infections, parent-reported upper respiratory tract illnesses, time to first upper r

89 An upper respiratory tract immunization (URTI) model was de

90 ontrol of B. bronchiseptica infection of the upper respiratory tract, immunization strategies aimed a

91 mia haemolytica, a commensal organism of the upper respiratory tract in cattle, is the principal bact

92 he ability to bind to receptors in the human upper respiratory tract in combination with several fami

93 erium and a common commensal organism of the upper respiratory tract in humans.

94 o colonize and persist in the lower, but not upper, respiratory tract in rats and mice.

95 The human upper respiratory tract, including the nasopharynx, is c

96 fluenza (13 [12%]), headache (11 [10%]), and upper respiratory tract infection (11 [10%]).

97 g vs nine [43%] patients receiving placebo), upper respiratory tract infection (11 [25%] patients vs

98 t infection (19 [7%] vs 11 [4%] vs 13 [5%]), upper respiratory tract infection (15 [5%] vs 15 [5%] vs

99 hesia (22 [10%] and 11 [5%] vs 10 [5%]), and upper respiratory tract infection (20 [9%] and 23 [11%]

100 tmares or abnormal dreams (4 [10%] vs none), upper respiratory tract infection (3 [7%] vs none], and

101 nasopharyngitis (30 [11%] vs 15 [11%]), and upper respiratory tract infection (35 [12%] vs ten [7%])

102 8.0%), sinusitis (4.0% and 6.3%), and viral upper respiratory tract infection (5.8% and 4.4%) for bu

103 The most common adverse events overall were upper respiratory tract infection (51 [9%] of 581 patien

104 7%] patients), rhinitis (10 [16%] patients), upper respiratory tract infection (7 [11%] patients), an

105 patients were headache (9% of the patients), upper respiratory tract infection (7%), and paresthesia

106 e events were fatigue (25%), headache (13%), upper respiratory tract infection (8%), and arthralgia (

107 brodalumab groups were nasopharyngitis (8%), upper respiratory tract infection (8%), and injection-si

108 te otitis media development, but symptomatic upper respiratory tract infection (as opposed to asympto

109 uded mild diarrhea (in 52% of the patients), upper respiratory tract infection (in 48%), nausea (in 4

110 The most frequent adverse events were upper respiratory tract infection (placebo 6 [7%] patien

111 significantly worse survival than those with upper respiratory tract infection (probable: hazard rati

112 erse events in both groups were headache and upper respiratory tract infection (ten [16%] for both ev

113 d with an increased risk of progression from upper respiratory tract infection (URI) to LRD.

114 surement properties in acute cough caused by upper respiratory tract infection (URTI) and longitudina

115 interval (months 1-6 and month 9) and during upper respiratory tract infection (URTI) episodes.

116 the association between vitamin D status and upper respiratory tract infection (URTI) have given mixe

117 y controls, whether to exclude controls with upper respiratory tract infection (URTI) or nonsevere pn

118 DYC was completed daily from the onset of an upper respiratory tract infection (URTI) until asthma sy

119 ts were grouped according to the presence of upper respiratory tract infection (URTI) without lower r

120 1) of the illness compared with infants with upper respiratory tract infection alone.

121 n used for respiratory syncytial virus (RSV) upper respiratory tract infection and lower respiratory

122 commonly reported adverse events (AEs) were upper respiratory tract infection and stomatitis of most

123 ren who present for elective surgery with an upper respiratory tract infection and suggests approache

124 At presentation, most patients (70%) had an upper respiratory tract infection and the remaining pati

125 who present for elective procedures with an upper respiratory tract infection are at increased risk

126 15 percent of samples from 261 patients with upper respiratory tract infection but in only 1 of 86 sa

127 A week before the onset of symptoms, a mild upper respiratory tract infection had developed.

128 Subjects with asthma and those with upper respiratory tract infection had values intermediat

129 at virulent HRV causes transient viremia and upper respiratory tract infection in addition to gastroi

130 ea in the pitavastatin group (n=12, 10%) and upper respiratory tract infection in the pravastatin gro

131 RSV usually presents as an upper respiratory tract infection in this patient popula

132 an important role in the pathogenesis of an upper respiratory tract infection induced by NTHI.

133 dministering anesthesia to the child with an upper respiratory tract infection is important in identi

134 roceed with anesthesia for the child with an upper respiratory tract infection is often difficult.

135 ast day their child exhibited symptoms of an upper respiratory tract infection or asthma exacerbation

136 ily a childhood disease that occurs after an upper respiratory tract infection or impetigo; its occur

137 st benefit of ribavirin-based therapy at the upper respiratory tract infection stage and the highest

138 itis media (AOM) is a common complication of upper respiratory tract infection whose pathogenesis inv

139 all expansion of CD8(+) T cells following an upper respiratory tract infection with a pathogenic infl

140 tract infection, 5.4%; otitis media, 12.2%; upper respiratory tract infection, 25.6%; bronchiolitis,

141 inflammatory bowel disease, 9 subjects with upper respiratory tract infection, and 16 subjects with

142 common adverse events were nausea, anaemia, upper respiratory tract infection, and headache.

143 ents in any tofacitinib group were diarrhea, upper respiratory tract infection, and headache; 21 pati

144 ommonly reported adverse events were asthma, upper respiratory tract infection, and headache; 9 patie

145 ced among groups, were most commonly asthma, upper respiratory tract infection, and injection site re

146 ent adverse events were injection-site pain, upper respiratory tract infection, and nausea.

147 r respiratory tract illnesses, time to first upper respiratory tract infection, and serum 25-hydroxyv

148 mab and placebo groups were dyspnoea, cough, upper respiratory tract infection, and worsening of IPF;

149 activated influenza vaccine, including acute upper respiratory tract infection, asthma, bronchiolitis

150 The most frequent AEs were fatigue, upper respiratory tract infection, cough, and dyspnea.

151 dache, peripheral edema, skin ulcer, anemia, upper respiratory tract infection, diarrhea, and nasopha

152 The most common AEs included arthralgia, upper respiratory tract infection, headache, fatigue, an

153 common adverse events were nasopharyngitis, upper respiratory tract infection, influenza, and back p

154 grade 3 infections (two lung infections, one upper respiratory tract infection, one sepsis, and one m

155 In this population of young children with upper respiratory tract infection, RV/EV accounted for t

156 iously healthy individuals with a history of upper respiratory tract infection, soft tissue contusion

157 Such common diagnoses as upper respiratory tract infection, urinary tract infecti

158 itis media occurs as a complication of viral upper respiratory tract infection.

159 ents were pulmonary exacerbation, cough, and upper respiratory tract infection.

160 well as reduction in the incidence of viral upper respiratory tract infection.

161 of epithelial signaling in the prevention of upper respiratory tract infection.

162 Common adverse events were headache and upper respiratory tract infection.

163 were headache, cough, nasal congestion, and upper respiratory tract infection.

164 the risk of acute otitis media complicating upper respiratory tract infection.

165 growth in human saliva, an ex vivo model of upper respiratory tract infection.

166 cription following a primary diagnosis of an upper respiratory tract infection.

167 nd included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could

168 of NO2 exposure in the week before or after upper respiratory-tract infection and the severity of as

169 ea (n=29, 18%, and n=16, 10%, respectively); upper-respiratory-tract infection (n=17, 10%) and periph

170 both (21 [20%] of 107 vs seven [6%] of 110), upper respiratory tract infections (18 [17%] vs ten [9%]

171 bo and 67 [29%] for reslizumab for study 2), upper respiratory tract infections (32 [13%] and 39 [16%

172 ts with dupilumab compared with placebo were upper respiratory tract infections (33-41% vs 35%) and i

173 .99; P =.04 for completing participants), or upper respiratory tract infections (44% vs 52%; RR, 0.84

174 appropriate antibiotic prescribing for acute upper respiratory tract infections (AURIs) requires a be

175 itis (eight [8%] patients in each group) and upper respiratory tract infections (five [5%] patients i

176 week 16, the most common adverse events were upper respiratory tract infections (four [4%], eight [8%

177 Common grade 1-2 toxicities included upper respiratory tract infections (in 28 [57%] of 49 pa

178 mporally associated with a recent history of upper respiratory tract infections (P = 0.0064), and mar

179 h a significant increase in the frequency of upper respiratory tract infections (r = -0.42, P < .001)

180 apneumovirus (hMPV) plays in the etiology of upper respiratory tract infections (URIs) in children ov

181 ysicians for the common cold and nonspecific upper respiratory tract infections (URTIs) (24%), acute

182 Information on upper respiratory tract infections (URTIs) and lower res

183 xyvitamin D (25-OHD) levels and incidence of upper respiratory tract infections (URTIs).

184 rovirus, are responsible for the majority of upper respiratory tract infections and are associated wi

185 d in dietary supplements, primarily to treat upper respiratory tract infections and to support immune

186 ntimicrobial prescribing practices for viral upper respiratory tract infections are being employed by

187 was the number of laboratory-confirmed viral upper respiratory tract infections based on parent-colle

188 Viral upper respiratory tract infections have been implicated

189 luster-level proportion of prescriptions for upper respiratory tract infections in 2-14-year-old outp

190 mation is available on the viral etiology of upper respiratory tract infections in Cameroon.

191 lus influenzae frequently causes noninvasive upper respiratory tract infections in children but can a

192 luenzae (NTHi) frequently causes noninvasive upper respiratory tract infections in children but can c

193 diagnosis of HIES plus hypereosinophilia and upper respiratory tract infections in the absence of par

194 entation reduces the incidence of wintertime upper respiratory tract infections in young children.

195 virulent human rotavirus (HRV) strains cause upper respiratory tract infections or viremia in gnotobi

196 The mean number of laboratory-confirmed upper respiratory tract infections per child was 1.05 (9

197 anging from 92.0% (95% CI, 89.9 to 94.1) for upper respiratory tract infections to 34.5% (95% CI, 31.

198 than either Victoria lineage and (ii) fewer upper respiratory tract infections were caused by the Vi

199 Upper respiratory tract infections were the most common

200 shares a receptor and a propensity to cause upper respiratory tract infections with the major group

201 ibiotic-inappropriate diagnoses (nonspecific upper respiratory tract infections, acute bronchitis, an

202 iotics were for the common cold, unspecified upper respiratory tract infections, and acute bronchitis

203 Infusion-related reactions, upper respiratory tract infections, and oral herpes infe

204 respiratory pathogens, and the occurrence of upper respiratory tract infections, including otitis med

205 ctive effect of vitamin E supplementation on upper respiratory tract infections, particularly the com

206 spitalized adults varies widely and includes upper respiratory tract infections, severe lower respira

207 ced prescribing of antibiotics for childhood upper respiratory tract infections.

208 n of T2Rs may have therapeutic potential for upper respiratory tract infections.

209 ementation did not reduce overall wintertime upper respiratory tract infections.

210 fects humans, causing significant numbers of upper respiratory tract infections.

211 operative adverse events among children with upper respiratory tract infections.

212 worldwide and represent the leading cause of upper respiratory tract infections.

213 yvitamin D levels and a higher risk of viral upper respiratory tract infections.

214 tion in children for the prevention of viral upper respiratory tract infections.

215 piratory-tract infections (3742 [55.3%]) and upper-respiratory-tract infections (1416 [20.9%]), of wh

216 principal etiologic agents of afebrile viral upper-respiratory-tract infections (the common cold).

217 ic obstructive pulmonary disease (COPD), and upper respiratory tract inflammation (URTI).

218 Upper respiratory tract inflammatory diseases such as as

219 ) infection induces clinical symptoms in the upper respiratory tract, inhibits immune responses, and

220 ) infection induces clinical symptoms in the upper respiratory tract, inhibits immune responses, and

221 e of transmitting virus after lower, but not upper, respiratory tract instillation and that this tran

222 Colonization of the upper respiratory tract is an initial step that may lead

223 The upper respiratory tract is continually assaulted with ha

224 lated with reduced numbers of macrophages in upper respiratory tract lavages as well as impaired upre

225 coronavirus for viral load in the lower and upper respiratory tracts (LRT and URT, respectively), bl

226 standing the composition and dynamics of the upper respiratory tract microbiota in healthy infants is

227 We sought to describe the dynamics of the upper respiratory tract microbiota in healthy infants wi

228 een N. meningitidis and other members of the upper respiratory tract microbiota, through a metabolic

229 commensal bacteria that colonizes the human upper respiratory tract mucosa during early childhood.

230 the bacterial communities at 2 sites of the upper respiratory tract obtained from children from a ru

231 in chickens and is limited in tropism to the upper respiratory tract of 1-day-old and 2-week-old chic

232 g and microbial community composition in the upper respiratory tract of 6-week-old infants.

233 tly, the virus replicated efficiently in the upper respiratory tract of domestic turkeys but with no

234 d in more-efficient viral replication in the upper respiratory tract of ferrets and an increased seru

235 n did the virus replicate efficiently in the upper respiratory tract of ferrets and became more immun

236 /107/03, which replicated efficiently in the upper respiratory tract of ferrets and was capable of tr

237 6-SA receptors replicated efficiently in the upper respiratory tract of ferrets, induced high levels

238 found in airways extending toward and in the upper respiratory tract of ferrets.

239 which we demonstrate commonly occurs in the upper respiratory tract of guinea pigs.

240 ed to high titers (> or =6.0 log(10)) in the upper respiratory tract of hamsters and to moderate tite

241 ed eight distinct microbiota profiles in the upper respiratory tract of healthy infants.

242 hat enhance colonization and survival in the upper respiratory tract of humans are well under way bef

243 for adaptation of HA to bind glycans in the upper respiratory tract of humans.

244 ated containment of viral replication in the upper respiratory tract of influenza virus-infected anim

245 replicate efficiently in the low temperature upper respiratory tract of mammals, suggesting the prese

246 Here, we show that coinfection of the upper respiratory tract of mice with influenza virus and

247 ne and equine viruses replicated well in the upper respiratory tract of mice.

248 identify the prevalence of 13 viruses in the upper respiratory tract of patients with CAP and concurr

249 jor role in facilitating colonization of the upper respiratory tract of rhesus macaques, in some case

250 nd to not be required for persistence in the upper respiratory tract of swine.

251 hat influenza B viruses can replicate in the upper respiratory tract of the guinea pig and that virus

252 ds on the surface of epithelial cells of the upper respiratory tract of the host using its own protei

253 tococcus pneumoniae frequently colonizes the upper respiratory tract of young children and is an impo

254 to examine influenza A virus kinetics in the upper respiratory tracts of experimentally infected adul

255 irus also demonstrated reduced titers in the upper respiratory tracts of ferrets; however, contact an

256 verse bacterial species that is found in the upper respiratory tracts of pigs and can also cause Glas

257 ay be useful for eliciting protection in the upper respiratory tracts of susceptible animals.

258 OM caused by other pathogens carried in the upper-respiratory tract of children.

259 e is known about either RSV infection of the upper respiratory tract or host mucosal immunity to RSV,

260 tle is known about T cell trafficking to the upper respiratory tract or the relationship between effe

261 ontrol and/or clear the bordetellae from the upper respiratory tract remain unclear.

262 The lymphoid tissue that drains the upper respiratory tract represents an important inductio

263 R ligands from the gastrointestinal, but not upper respiratory, tract rescued host defenses in the lu

264 d restricted in replication in the lower and upper respiratory tract, respectively, compared to wild-

265 r probable LRTI, respectively) or a positive upper respiratory tract sample with radiographic abnorma

266 her MERS-CoV loads and genome fractions than upper respiratory tract samples.

267 n obtaining samples without contamination by upper respiratory tract secretions.

268 e detection of S. pneumoniae or S. aureus in upper respiratory tract secretions; however, the specime

269 and that the virus is highly tropic for the upper respiratory tract, so testing of bird species shou

270 d efficient extraction of nucleic acids from upper respiratory tract specimens (nasal washes and swab

271 The most common virus detected in upper respiratory tract specimens was EV-D68 (from 20%,

272 r specificity (eg, detection of pathogens in upper respiratory tract specimens, which may indicate as

273 l glands and surface epithelial cells of the upper respiratory tract, SPLUNC1 is thought to possess a

274 nificantly decreased ability to colonize the upper respiratory tract, suggesting that cleavage of cor

275 ulum pigrum is a commensal inhabitant of the upper respiratory tract suspected to be responsible for

276 ssociated with each other and with lower and upper respiratory tract symptoms when assessed longitudi

277 ed from 81 children under 1 year of age with upper respiratory tract symptoms.

278 with the novel genotype were associated with upper-respiratory-tract symptoms but, more frequently, w

279 rganisms are obligate parasites of the human upper respiratory tract that can exist as commensals or

280 moniae forms organized biofilms in the human upper respiratory tract that may play an essential role

281 Kingella kingae is a commensal of the upper respiratory tract that occasionally causes skeleta

282 obligate commensal and pathogen of the human upper respiratory tract, to adapt to changes in the host

283 pithelial (NHBE) cells, a model of the human upper respiratory tract, to examine the replicative capa

284 viruses replicated to similar titers in the upper respiratory tract (URT) and caused comparable dise

285 mpounds active against carcinogenesis of the upper respiratory tract (URT) has been largely unsuccess

286 The upper respiratory tract (URT) hosts a complex microbial

287 c inference of identifying a pathogen in the upper respiratory tract (URT) of children with pneumonia

288 f PVRL4 was widespread in both the lower and upper respiratory tract (URT) of macaques, indicating MV

289 Most infants suffer mild upper respiratory tract (URT) symptoms, whereas approxim

290 milar to that of a mild low-dose, low-volume upper respiratory tract (URT)-biased infection.

291 sible caused limited tissue pathology in the upper respiratory tract (URT).

292 eration of local immune responses within the upper respiratory tract (URT).

293 penicillin-susceptible (PEN-S) ancestors for upper-respiratory-tract (URT) colonization.

294 ticle aerosols of Y. pestis in the lower and upper respiratory tracts (URTs) of mice are different.

295 lower respiratory tract, rather than in the upper respiratory tract, where resident microflora and i

296 ad domain in reduction of viral loads in the upper respiratory tract, which could significantly reduc

297 is) is the granulomatous inflammation of the upper respiratory tract, which leads to the subsequent d

298 icient replication of the pH1N1 virus in the upper respiratory tract, which resulted in efficient hum

299 TD into 3 groups: possible (PIV detection in upper respiratory tract with new pulmonary infiltrates w

300 lus influenzae typically colonizes the human upper respiratory tract without causing disease, and yet